TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Tumor-associated macrophages (TAMs) are heterogeneous and can adopt a spectrum of activation states between pro-inflammatory and pro-tumorigenic in response to the microenvironment. We have previously shown that TTI-621, a soluble SIRPαFc fusion protein that blocks the CD47 "do-not-eat" si...
Main Authors: | Gloria H Y Lin, Vien Chai, Vivian Lee, Karen Dodge, Tran Truong, Mark Wong, Lisa D Johnson, Emma Linderoth, Xinli Pang, Jeff Winston, Penka S Petrova, Robert A Uger, Natasja N Viller |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5662218?pdf=render |
Similar Items
-
Role of the CD47/SIRPα-interaction in regulation of macrophage phagocytosis
by: Olsson, Mattias
Published: (2008) -
The Immunotherapeutic Effect of SIRPα-Silenced DCs against Cervical Cancer
by: Xiaojie Li, et al.
Published: (2020-01-01) -
Attenuation of CD47-SIRPα Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic Metastasis
by: Kulthida Vaeteewoottacharn, et al.
Published: (2019-02-01) -
Characterisation of the SIRP gene family and CD47 viral homologues
by: Cochrane, Fiona Gutiez
Published: (2005) -
CD47–SIRPα : an interaction of importance for bone cell differentiation
by: Koskinen, Cecilia
Published: (2014)